REGN Regeneron Pharmaceuticals Loading... : Bullish and Bearish Analyst Opinions
From REGN earnings callsLoading chart...
Top Calls
Feed
12:30
Jul 30
Jul 30
Management expresses a bullish outlook on the pipeline, including multiple launches and readouts ahead, while noting moderating growth for Dupixent later in the year.
HIGH
12:30
Apr 29
Apr 29
Management tone is positive, highlighting strong Q1 results with double-digit growth and a robust pipeline, with expectations for continued momentum.
HIGH
13:30
Jan 30
Jan 30
Management is confident in the near-term outlook, highlighted by strong commercial execution, a late-stage pipeline (including key readouts in melanoma and myasthenia gravis), and multiple planned FDA approvals in 2026.
HIGH
About REGN Analyst Coverage
Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Dr. Leonard Schleifer, Ryan Crow.